US equities |
INTC $65.58 ▼-28.77% AMZN $236.79 ▼-2.87% MU $892.93 ▼-4.42% NVDA $206.37 ▼-3.41% SNDK $1,214.72 ▼-8.67% GOOGL $280.85 ▼-1.05% AMD $512.91 ▼-9.45% AAPL $344.90 ▼-1.15%
FinancialContent

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

0.9019 -0.0028 (-0.31%)
Delayed Quote Updated: 9:40 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week ↗
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025. 
Via Stocktwits
News headline image
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study ↗
Tiziana Life Sciences recently discovered new immune biomarkers in SPMS patients treated with nasal foralumab. 
Via Benzinga
News headline image
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus ↗
U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump's Loss ↗
Tesla Inc (NASDAQ: TLSA) and SpaceX, chief executive officer, Elon Musk sparked a new controversy by saying that Jeff Bezos, the founder and executive chairman of Amazon.com, predicted President-elect... 
Via Benzinga
Topics Government
News headline image
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Cathie Wood Redirects Elon Musk's DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here's How Oklo, Cameco, Centrus Energy And Other Stocks Performed ↗
Nuclear energy stocks and ETFs have come to the fore as ARK Invest's founder Cathie Wood reshared the firm's study on how regulatory hurdles and anti-nuclear sentiment have caused cost overruns and... 
Via Benzinga
Topics ETFs Energy
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >